Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

CELGENE CORPORATION (CELG)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/18/2018 06/19/2018 06/20/2018 06/21/2018 06/22/2018 Date
77.73(c) 79.44(c) 79.77(c) 79.14(c) 78.8(c) Last
6 972 175 8 047 600 6 913 609 4 411 196 5 353 062 Volume
-0.45% +2.20% +0.42% -0.79% -0.43% Change
More quotes
Financials (USD)
Sales 2018 14 908 M
EBIT 2018 8 447 M
Net income 2018 4 829 M
Debt 2018 6 033 M
Yield 2018 -
Sales 2019 16 724 M
EBIT 2019 9 595 M
Net income 2019 6 238 M
Finance 2019 3 400 M
Yield 2019 -
P/E ratio 2018 12,42
P/E ratio 2019 9,80
EV / Sales2018 4,28x
EV / Sales2019 3,25x
Capitalization 57 819 M
More Financials
Company
Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases.Its targeting areas include intracellular signaling pathways, protein homeostasis and epigenetics in... 
Sector
Pharmaceuticals
Calendar
07/26Earnings Release
More about the company
Surperformance© ratings of Celgene Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on CELGENE CORPORATION
01:53pCELGENE CORPORATION : Announces Appointment of Jonathan Biller as Executive Vice..
AQ
10:23aCelgenes CAR T Cell Therapy Could Be Long-Term Growth Driver
AQ
06/21Complimentary Technical Snapshots on Celgene and Three More Biotech Stocks
AC
06/20ACCELERON PHARMA : Announces Updated Results from Ongoing Phase 2 Trials of Lusp..
AQ
06/19CELGENE CORP /DE/ : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
06/19CELGENE CORPORATION : Announces Appointment of Jonathan Biller as Executive Vice..
BU
06/19NASDAQ 100 MOVERS : Jd, regn
AQ
06/19ELOXX PHARMACEUTICALS : Appoints Global Pharmaceutical Leader, Neil Belloff, Exe..
AQ
06/19Payers, drugmakers face off over CAR T Medicare coverage
AQ
06/15CELGENE : CREATES could face uphill battle in Senate
AQ
More news
Sector news : Pharmaceuticals - NEC
11:16aSHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
07:38aRoche to Appoint James Sabry as Head of Partnering
DJ
06/21LONDON MARKETS: FTSE 100 Drops As Oil Shares Extend Losses; Pound Rallies On ..
DJ
06/21Canada sets October start for legal recreational marijuana sales
RE
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on CELGENE CORPORATION 
CELGENE CORPORATION - 2017
The resistance should give in
BUY
CELGENE CORPORATION - 2017
Hesitation should subside in favor of volatility
BUY
More Strategies
Latest Tweets
02:10pMarket Trends Toward New Normal in RCI Hospitality, Phillips 66 Partners LP, .. 
06/20Celgene Corporation Announces Appointment of Jonathan Biller as Executive Vic.. 
06/20A Look Back At What's Happened To Each Sector Through The First Half Of 2018 ..
2
06/19$CELG New SEC Document(s) for Celgene Corporation From our Stock News Alerts .. 
06/19$CELG Celgene Corporation Announces Appointment of Jonathan Biller as Executi.. 
More tweets
Qtime:638
News from SeekingAlpha
06/21Forty Seven Readies $100 Million U.S. IPO 
06/183 THINGS IN BIOTECH, JUNE 17 : Ruxolitinib Climbs Higher 
06/18Tandem Diabetes Care Has Run Up A Lot - Cramer's Lightning Round (6/15/18) 
06/18Epizyme Continues To Chug Along Despite FDA Partial Clinical Hold 
06/15Brief Mid-Year Update On 2018 Global Asset Allocation 
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 113 $
Spread / Average Target 43%
EPS Revisions
Managers
NameTitle
Mark J. Alles Chairman, President, CEO & COO
Peter N. Kellogg Executive VP, Chief Financial & Accounting Officer
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Jay T. Backstrom Chief Medical Officer
Rupert J. Vessey President-Research & Early Development
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION-23.88%57 819
JOHNSON & JOHNSON-12.27%327 330
PFIZER0.00%213 275
NOVARTIS-10.87%189 575
ROCHE HOLDING LTD.-12.58%188 417
MERCK AND COMPANY8.90%164 862